An experimental study found that CD226 deficiency in CD4 + T cells attenuated airway hyperresponsiveness in asthma in mice, thus validating that targeting CD226 may provide new ideas for the clinical treatment of asthma [46]. This evidence concerns the gene CD226 and airway hyperresponsiveness.